Feature|Articles|November 13, 2025
Day 1 Recap: Elevate-Derm Fall Conference
Listen
0:00 / 0:00
Key Takeaways
- Dupilumab significantly enhances growth and reduces corticosteroid use in children with severe atopic dermatitis, as presented at Elevate-Derm.
- New therapeutic strategies for dermatological conditions include low-dose oral minoxidil, off-label JAK inhibitors, Thiamidol, and delgocitinib.
Catch up on coverage from the first day of the 2025 Elevate-Derm Fall Conference.
Advertisement
To stay informed with the latest conference insights, follow us on social media and
Previewing the 2025 Elevate-Derm Fall Conference
Matthew Brunner, MHS, PA-C, discusses upcoming highlights of the 6th annual meeting for dermatology NPs and PAs.
Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients
A poster presented at Elevate-Derm found dupilumab significantly enhanced growth and reduces corticosteroid use in children with severe atopic dermatitis.
Topical and Systemic Tools Expand Options for Hair Loss, Pigmentary Disorders, and Hand Eczema
Victoria Garcia-Albea, NP, outlined evolving therapeutic strategies at Elevate-Derm Fall, highlighting low-dose oral minoxidil, off-label JAK inhibition for frontal fibrosing alopecia, Thiamidol in hyperpigmentation, and delgocitinib for chronic hand eczema.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
